Whether CYP1A2 is useful for longevity is not clearly supported by current evidence. CYP1A2 encodes an enzyme primarily involved in caffeine and drug metabolism. Some observational studies suggest that caffeine's effects on cardiovascular health may vary by CYP1A2 genotype, but effect sizes are small and no robust longitudinal data directly link this gene to lifespan extension. Evidence is limited to mechanistic and GWAS-based associations. Commercial DNA tests often market CYP1A2 as a 'caffeine metabolizer' trait, which oversimplifies the biology. For longevity assessment, better-validated markers include inflammatory biomarkers, telomere length, and epigenetic clocks. A standalone CYP1A2 test does not provide actionable longevity guidance. Consumers should be cautious of exaggerated marketing claims.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-f03535a92bddd16a1b7a9991